Oezcueruemez-Porsch M, Kunz D, Hardt P D, Fadgyas T, Kress O, Schulz H U, Schnell-Kretschmer H, Temme H, Westphal S, Luley C, Kloer H U
Third Department of Internal Medicine, University of Giessen, Germany.
Dig Dis Sci. 1998 Aug;43(8):1763-9. doi: 10.1023/a:1018887704337.
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis has been suggested as a model for acute pancreatitis (AP), which allows evaluation of early alterations in the time course of the disease. The influence of the clinical course on procalcitonin (PCT), serum amyloid A (SAA), and several proinflammatory and inhibitory cytokines was evaluated in patients with AP following ERCP. Blood samples were prospectively collected from patients undergoing ERCP. The incidence of ERCP-induced pancreatic damage, defined as abdominal complaints, a threefold increase of serum lipase, and elevation of CRP from <10 to >20 mg/liter was 12.8% (12/94). Only mild clinical courses of acute pancreatitis were observed. PCT significantly increased in subjects with post-ERCP pancreatitis after 24 hr. However, PCT levels did not exceed 0.5 ng/ml in any patient. Interleukin-1 receptor antagonist (IL-1RA) began to differ from baseline 2 hr after ERCP, followed by interleukin-6 (IL-6, 6 hr), solubilized tumor necrosis factor-alpha receptor II (sTNF-alphaRII, 24 hr) and SAA (24 hr). Interleukin 10 (IL-10) showed marked interindividual variations with no obvious peak. Among all parameters evaluated, only peak values of IL-6 and IL-10 showed significant correlations with the reported pain score (r2 = 0.62/0.78), degree of ampullar irritation (r2 = NS/0.87), and the duration of ERCP (r2 = 0.58/0.76). No correlation was found with the volume of the injected contrast agent. We conclude that IL-10 and IL-6 appear to be useful to monitor patients after ERCP. The absence of any PCT elevation in the present study is in accordance with the clinical course of the patients who suffered from mild pancreatic damage without systemic or infectious complications.
内镜逆行胰胆管造影术(ERCP)后胰腺炎被认为是急性胰腺炎(AP)的一种模型,它有助于评估疾病进程中的早期变化。本研究评估了临床病程对ERCP术后AP患者降钙素原(PCT)、血清淀粉样蛋白A(SAA)以及多种促炎和抗炎细胞因子的影响。前瞻性收集接受ERCP患者的血样。ERCP诱发胰腺损伤的发生率(定义为出现腹部不适、血清脂肪酶升高3倍以及CRP从<10 mg/L升高至>20 mg/L)为12.8%(12/94)。仅观察到急性胰腺炎的轻度临床病程。ERCP术后胰腺炎患者的PCT在24小时后显著升高。然而,所有患者的PCT水平均未超过0.5 ng/ml。白细胞介素-1受体拮抗剂(IL-1RA)在ERCP术后2小时开始与基线水平出现差异,随后是白细胞介素-6(IL-6,6小时)、可溶性肿瘤坏死因子-α受体II(sTNF-αRII,24小时)和SAA(24小时)。白细胞介素10(IL-10)表现出明显的个体差异,无明显峰值。在所有评估参数中,只有IL-6和IL-10的峰值与报告的疼痛评分(r2 = 0.62/0.78)、壶腹刺激程度(r2 = 无显著性差异/0.87)以及ERCP持续时间(r2 = 0.58/0.76)显著相关。未发现与注入造影剂的量相关。我们得出结论,IL-10和IL-6似乎有助于监测ERCP术后的患者。本研究中未出现任何PCT升高的情况,这与患有轻度胰腺损伤且无全身或感染并发症患者的临床病程一致。